LHG - Litha Healthcare Group Limited - Litha Healthcare Group Limited Acquires

LHG - Litha Healthcare Group Limited - Litha Healthcare Group Limited Acquires  
Goldex Healthcare                                                               
LITHA HEALTHCARE GROUP LIMITED                                                  
(Formerly Myriad Medical Holding Limited)                                       
Incorporated in the Republic of South Africa                                    
(Registration number 2006/006371/06)                                            
Share code: LHG ISIN:ZAE000144671                                               
("Litha" or "the company")                                                      
LITHA HEALTHCARE GROUP LIMITED ACQUIRES GOLDEX HEALTHCARE                       
The acquisition which forms part of the group`s Pharma Division strategy, will  
result in the company rapidly expanding its pharmaceutical pipeline             
Litha Healthcare Group, a JSE listed healthcare company, has signed an agreement
to acquire Goldex Healthcare, a Durban-based pharmaceutical company. The cash   
deal sees Litha obtaining a 100 % share in the company, for a total value R 33  
Million and is being funded through internally generated cash. Goldex is an     
approved manufacturer and distributor of its own pharmaceutical products, as    
well as an exclusive distributor, under license, for Unichem Laboratories Ltd, a
leading Indian multinational. By acquiring and integrating the Goldex product   
range, the Litha Healthcare Group will build scale and secure product pipelines 
for its Litha Pharma Division.                                                  
The company`s products comprise;  prescription and over-the-counter (OTC)       
medicines which include amongst others; Cold & Flu Preparations, Mouth & Throat 
Preparations, Dermatological Preparations, Ophthalmic Preparations, Ear, Nose & 
Throat preparations, Anti-inflammatories / Analgesics, Anti-microbials,         
Antihistamines, Cardiovascular Agents and Vitamin supplements.                  
Goldex Healthcare promotes products such as Sinustat throughout South Africa and
its product line currently holds 32 active pharmaceutical products which include
mainly generic as well as some innovator brands.  There are also a number of    
products awaiting registration at the Medical Control Council (MCC).            
"Realising the need for continuity, Litha and Goldex Healthcare have agreed to  
an eight month handover period until December this year, during which time      
Goldex will continue to operate from its Durban premises, with the entire       
operational staff remaining in place. Thereafter, Litha Group will transfer the 
Goldex business to our headquarters in Johannesburg. We anticipate that the     
longer handover period will ensure a smooth transition of the Goldex business   
into the Litha Group, `` says Selwyn Kahanovitz, Group CEO, Litha Healthcare    
Group Limited.                                                                  
Kahanovitz adds, "Brett Ryan, the Commercial and Sales Manager for Goldex       
Healthcare, will continue in his current position and will together with Litha  
Pharma, increase the current Goldex sales force, with further investment and    
promotion of the Goldex product range."                                         
During the past three years, Goldex has experienced considerable growth and     
success in the generic pharmaceutical sector in Southern Africa. Part of this   
growth has been due to their strong and valued relationship with Unichem India. 
"With the current portfolio of Goldex and Unichem products, together with the   
pipeline of products awaiting MCC registration, we are excited about the        
positive boost to the size of the overall product range within the Litha Pharma 
Division," concludes Kahanovitz.                                                
3 May 2011                                                                      
Sponsor                                                                         
Java Capital                                                                    
Date: 03/05/2011 16:32:01 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.